Aligos Therapeutics (NASDAQ:ALGS) Stock Bumped Down to “Sell” by Wall Street Zen

Wall Street Zen lowered shares of Aligos Therapeutics (NASDAQ:ALGS – Free Report) from a hold rating to a sell rating in a research report report published on Saturday,Wall Street Zen reports.

Several other analysts have also weighed in on the stock. Weiss Ratings lowered shares of Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, September 16th. HC Wainwright reiterated a “buy” rating on shares of Aligos Therapeutics in a research report on Monday, August 10th. Finally, Jefferies Financial Group started coverage on shares of Aligos Therapeutics in a research note on Monday, November 9th. They set a “strong-buy” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $38.50.

Check Out Our Latest Report on ALGS

Aligos Therapeutics Trading Up 6.1%

NASDAQ ALGS traded up $0.12 during trading hours on Friday, hitting $2.10. 57,432 shares of the company’s stock were exchanged, compared to its average volume of 65,505. The firm has a market cap of $13.12 million, a price-to-earnings ratio of -0.33 and a beta of 2.43. The stock has a 50-day simple moving average of $4.94 and a 200 day simple moving average of $6.03. Aligos Therapeutics has a 1-year low of $1.92 and a 1-year high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) last issued its quarterly earnings results on Friday, November 6th. The company reported ($2.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.28) by $0.19. The firm had revenue of $2.87 million for the quarter, compared to analyst estimates of $4.85 million. Aligos Therapeutics had a negative return on equity of 206.30% and a negative net margin of 197.01%. On average, sell-side analysts anticipate that Aligos Therapeutics will post -6.61 earnings per share for the current fiscal year.

Institutional Trading of Aligos Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALGS. SummitTX Capital L.P. raised its holdings in Aligos Therapeutics by 6.7% during the first quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after buying an additional 9,375 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Aligos Therapeutics by 17.6% in the first quarter. Renaissance Technologies LLC now owns 100,450 shares of the company’s stock valued at $746,000 after buying an additional 15,006 shares in the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of Aligos Therapeutics by 1,652.8% during the first quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock valued at $1,707,000 after buying an additional 216,646 shares during the last quarter. 60.43% of the stock is owned by institutional investors.

Aligos Therapeutics Company Profile

(Get Free Report)

Aligos Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. Founded in 2018, it focuses on developing medicines for viral infections and liver diseases. The company’s research has included investigational treatments for chronic hepatitis B and metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. Its development work has involved small-molecule drug candidates, including approaches intended to interfere with viral replication.

Recommended Stories

Analyst Recommendations for Aligos Therapeutics (NASDAQ:ALGS)

Receive News & Ratings for Aligos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aligos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.